BackTeva- Pharmaceutical Industries Overview

Teva- Pharmaceutical Industries Current Assets

Teva- Pharmaceutical Industries's current assets is $14B.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$13.76B
9.03% YoYΔ $1.14B vs prior year quarter

Peer average / median

Loading

Teva- Pharmaceutical Industries Current Assets History

Loading

Teva- Pharmaceutical Industries vs. peers: Current Assets Comparison

Loading

Teva- Pharmaceutical Industries Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Teva- Pharmaceutical Industries (TEVA) FAQ

The latest current assets for TEVA is $14B as of June 2026. That compares with $13B in the prior-year period — up 9.0% year over year. Investors often review this figure alongside Teva- Pharmaceutical Industries's historical trend and sector peers before judging valuation or financial health.

Over the past year, TEVA's current assets moved from $13B to $14B — a 9.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Teva- Pharmaceutical Industries's operating scale or balance-sheet position.

A current assets figure of $14B for TEVA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TEVA's current assets ($14B), review year-over-year change from $13B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Teva- Pharmaceutical Industries's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.